Fig. 6

Inhibition of IL-6R/JAK/STAT pathway by miR-155 A) IL-6 was added to cardiomyocytes at 50 ng/mL for 24 h, and the number of cardiomyocytes labeled with pH3 or ki67 was observed by immunocytochemistry. Scale bar: 400 μm. *P < 0.05 and ***P < 0.001, IL-6 vs. mock treatment. B) Negative control or miR-155 mimic transfected cardiomyocytes at 100nM for 24 h, and then IL-6 was added at 50 ng/mL for 24 h. The number of cardiomyocytes labeled with pH3 or ki67 was observed by immunocytochemistry. Scale bar: 400 μm. *P < 0.05 and **P < 0.01, IL-6 vs. PBS treatment. ##P < 0.01 and ###P < 0.001, miR-155 vs. NC treatment. C) Negative control or miR-155 mimic transfected cardiomyocytes at 100 nM for 24 h, and then IL-6 was added for 24 h. Immunoblotting was performed with IL-6R, phospho-Jak2, and phospho-Stat3 antibodies. GAPDH was used as a loading control. Each experiment in this figure was replicated more than three times